174 related articles for article (PubMed ID: 34785028)
1. Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study
Lescoat A; Murphy SL; Chen YT; Vann N; Galdo FD; Cella D; Buch MH; Khanna D
Semin Arthritis Rheum; 2022 Feb; 52():151926. PubMed ID: 34785028
[TBL] [Abstract][Full Text] [Related]
2. Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.
Pauling JD; Domsic RT; Saketkoo LA; Almeida C; Withey J; Jay H; Frech TM; Ingegnoli F; Dures E; Robson J; McHugh NJ; Herrick AL; Matucci-Cerinic M; Khanna D; Hewlett S
Arthritis Care Res (Hoboken); 2018 Sep; 70(9):1373-1384. PubMed ID: 29473715
[TBL] [Abstract][Full Text] [Related]
3. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry.
Tolosa-Vilella C; Morera-Morales ML; Simeón-Aznar CP; Marí-Alfonso B; Colunga-Arguelles D; Callejas Rubio JL; Rubio-Rivas M; Freire-Dapena M; Guillén-Del Castillo A; Iniesta-Arandia N; Castillo-Palma MJ; Egurbide-Arberas M; Trapiellla-Martínez L; Vargas-Hitos JA; Todolí-Parra JA; Rodriguez-Carballeira M; Marin-Ballvé A; Pla-Salas X; Rios-Blanco JJ; Fonollosa-Pla V;
Semin Arthritis Rheum; 2016 Oct; 46(2):200-208. PubMed ID: 27312381
[TBL] [Abstract][Full Text] [Related]
4. Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches.
Volkmann ER; Furst DE
Rheum Dis Clin North Am; 2015 Aug; 41(3):399-417. PubMed ID: 26210126
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of endothelial dysfunction and clinical events in patients with early-stage vasculopathy in limited systemic sclerosis.
Jud P; Meinitzer A; Strohmaier H; Schwantzer G; Foris V; Kovacs G; Avian A; Odler B; Moazedi-Fürst F; Brodmann M; Hafner F
Clin Exp Rheumatol; 2021; 39 Suppl 131(4):57-65. PubMed ID: 34323684
[TBL] [Abstract][Full Text] [Related]
6. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis.
Gliddon AE; Doré CJ; Maddison PJ;
Arthritis Rheum; 2006 Jun; 55(3):473-9. PubMed ID: 16739187
[TBL] [Abstract][Full Text] [Related]
7. Systemic sclerosis sine scleroderma and limited cutaneous systemic sclerosis: similarities and differences.
Simeón-Aznar CP; Tolosa-Vilella C; Gabarró-Juliá L; Campillo-Grau M; Guillén Del Castillo A; Fonollosa-Plá V; Vilardell-Tarrés M
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-33-40. PubMed ID: 24776173
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis.
Hughes M; Pauling JD; Jones J; Denton CP; Domsic RT; Frech TM; Herrick AL; Khanna D; Matucci-Cerinic M; McKenzie L; Saketkoo LA; Gooberman-Hill R; Moore A
Arthritis Care Res (Hoboken); 2020 May; 72(5):723-733. PubMed ID: 31841265
[TBL] [Abstract][Full Text] [Related]
9. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
[TBL] [Abstract][Full Text] [Related]
10. The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis.
Hughes M; Huang S; Pauling JD; Sabbagh M; Khanna D
Clin Rheumatol; 2022 Oct; 41(10):3049-3054. PubMed ID: 35583625
[TBL] [Abstract][Full Text] [Related]
11. Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: an international collaborative scoping review.
Lescoat A; Sandler RD; Zimmermann F; Roofeh D; Hughes M; Pauling JD; Murphy SL; Chen YT; Townsend W; Buch MH; Khanna D
Rheumatology (Oxford); 2022 Aug; 61(8):3132-3148. PubMed ID: 35094049
[TBL] [Abstract][Full Text] [Related]
12. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.
Silva C; Solanki KK; White DHN
Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326
[TBL] [Abstract][Full Text] [Related]
13. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
14. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
[TBL] [Abstract][Full Text] [Related]
15. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
16. Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort.
Foeldvari I; Klotsche J; Kasapcopur O; Adrovic A; Terreri MT; Sakamoto AP; Stanevicha V; Sztajnbok F; Anton J; Feldman B; Alexeeva E; Katsicas M; Smith V; Avcin T; Marrani E; Kostik M; Lehman T; Sifuentes-Giraldo WA; Vasquez-Canizares N; Appenzeller S; Janarthanan M; Moll M; Nemcova D; Patwardhan A; Santos MJ; Sawhney S; Schonenberg-Meinema D; Battagliotti C; Berntson L; Bica B; Brunner J; Costa-Reis P; Eleftheriou D; Harel L; Horneff G; Kaiser D; Kallinich T; Lazarevic D; Minden K; Nielsen S; Nuruzzaman F; Uziel Y; Helmus N; Torok KS
Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1575-1584. PubMed ID: 33787070
[TBL] [Abstract][Full Text] [Related]
17. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.
Gliddon AE; Doré CJ; Black CM; McHugh N; Moots R; Denton CP; Herrick A; Barnes T; Camilleri J; Chakravarty K; Emery P; Griffiths B; Hopkinson ND; Hickling P; Lanyon P; Laversuch C; Lawson T; Mallya R; Nisar M; Rhys-Dillon C; Sheeran T; Maddison PJ
Arthritis Rheum; 2007 Nov; 56(11):3837-46. PubMed ID: 17968938
[TBL] [Abstract][Full Text] [Related]
18. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
19. Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020.
Maltez N; Hughes M; Brown E; Hickey V; Park H; Shea B; Herrick AL; Pauling JD; Proudman S; Merkel PA
Semin Arthritis Rheum; 2021 Jun; 51(3):640-643. PubMed ID: 33947582
[TBL] [Abstract][Full Text] [Related]
20. Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes.
Lescoat A; Murphy SL; Roofeh D; Pauling JD; Hughes M; Sandler R; Zimmermann F; Wessel R; Townsend W; Chung L; Denton CP; Merkel PA; Steen V; Allanore Y; Del Galdo F; Godard D; Cella D; Farrington S; Buch MH; Khanna D
J Scleroderma Relat Disord; 2021 Feb; 6(1):66-76. PubMed ID: 34316516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
